endpoint retained Crosstree to assist with growth funding, and the result was a minority investment by Chiltern.
Please direct inquiries to:
Shane C. Senior, CFA
Crosstree Capital Partners, Inc.
With prior experience in developing, running, and selling a successful IVR company for the clinical R&D market, endpoint's founders knew the challenges that lay ahead for the company. Endpoint retained Crosstree to assist with finding a strategic partner to finance the new venture, rather than more expensive venture funding.
Crosstree brought Chiltern to the table, who became interested in endpoint's technology. Chiltern invested in the company, giving endpoint crucial growth capital, and the ability to leverage Chiltern's infrastructure, clients, and business development. Chiltern gained a competitive technology differentiation through this transaction.
endpoint is an innovative company dedicated to the development of the leading Interactive Response Technology (IVR/IWR) platforms for the life sciences industry. endpoint's founding team members have been developing IRT systems for clinical trials since 1998 and have deployed systems to small, medium and large pharma and biotech companies for domestic and global studies with experience across a broad range of therapeutic areas and global implementations.
Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries, has 24 offices and legal entities within 20 countries, resources in 37 countries and employs nearly 1,400 people globally. Chiltern provides Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services.
"LONDON, March 31 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO) announced a strategic partnership with endpoint. With this investment, Chiltern becomes a minority shareholder in the company established in April 2009.
Glenn Kerkhof, Chiltern CEO, stated, "Chiltern's decision to invest in endpoint is representative of our commitment to seek collaborations which connect Chiltern and our clients with leading edge solutions as well as our belief in the technology that endpoint has developed. Jon Dole and Tom O'Connell are bringing a new level of energy and innovation to Interactive Response Technology services to provide solutions which are meeting clients' needs for flexibility, efficiency and savings while ensuring the highest possible quality. We believe that endpoint has listened - and is responding - to the industry's needs for IVR/IWR solutions and we look forward to introducing endpoint to our customers as a Chiltern qualified vendor that will meet their needs and exceed their expectations in a manner that mirrors Chiltern's commitment to the same."
Jonathan Dole, endpoint CEO, stated, "Chiltern's enthusiasm and investment affirms our confidence in the solutions we are bringing to the marketplace. At endpoint, we are delighting our clients with approaches that are exceeding their needs. Our experience in the IVR/IWR space, coupled with a fresh and logical approach to systems development, is giving our customers the agility they need in a constantly changing R&D environment. We are very pleased to be working closely with Chiltern to identify and act on opportunities for synergies across our two organizations."
Crosstree Capital Partners was the exclusive advisor for endpoint.
Crosstree Capital Partners is a specialty advisory firm with a dedicated focus on select subsectors of the life sciences and healthcare industries, including drug and device outsourcing, diagnostic products and services, life sciences tools, medical technology, and healthcare information technology. Within these subsectors, Crosstree assists clients with corporate finance activities, including mergers and acquisitions advisory and growth capital financings. Crosstree's deep sector coverage offers clients unique industry insights, well-established strategic relationships across the globe and superior access to the capital markets. While Crosstree draws distinct industry lines of coverage, the firm has no geographic boundaries. Crosstree has advised clients throughout North America, Europe, India, China, Latin America and Australia. Crosstree Capital Partners, Inc. is an affiliate of Crosstree Capital Securities, LLC, which is a member of FINRA and SIPC. Crosstree’s website is http://www.crosstreecapital.com.
Crosstree Capital Partners is a micro-industry focused investment bank, providing strategic advisory services, including mergers and acquisitions, recapitalizations, and growth capital placements, to leading clients within its focused industries.
Crosstree is the leading source of related valuation and transactional data for its focus industries. Publications are available exclusively to website subscribers on dedicated industry portals. To access Crosstree’s proprietary industry portals and related publications and data, please login or click here to join.
Copyright © 2012 • Crosstree Capital Partners • All rights reserved•